Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,058 recalls, newest first

Class II · Moderate risk

Vecuronium Bromide for Injection

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-2914-01 D-0279-2021
Class II · Moderate risk

Toposar (etoposide injection USP)

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-5657-01 D-0278-2021
Class II · Moderate risk

Metoclopramide Injection USP

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-4502-01 D-0277-2021
Class II · Moderate risk

Leucovorin Calcium for Injection

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-5140-01 D-0276-2021
Class II · Moderate risk

MethyIPREDNISolone Acetate Injectable Suspension USP

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-0031-01 D-0275-2021
Class II · Moderate risk

Epoprostenol Sodium for Injection

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-1985-01 D-0274-2021
Class II · Moderate risk

Sterile Diluent for Epoprostenol Sodium for Injection

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-9258-01 D-0273-2021
Class II · Moderate risk

Desmopressin Acetate Injection USP

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-5051-01 D-0272-2021
Class II · Moderate risk

Dacarbazine for Injection USP

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-5075-01 D-0271-2021
Class III · Low risk

Glycopyrrolate Injection

Labeling; Label Mix-up; correctly labeled 2 mL vials were packaged into blister strips labeled for 1 mL vials

Terminated Labeling / mix-up Accord Healthcare, Inc. NDC 16729-472-08 D-0250-2021
Class I · High risk

Cisatracurium Besylate Injection

Labeling: Label mix-up: Carton of Cisatracurium Besylate Injection, USP was observed to contain ten vials mislabeled as Phenylephrine Hydrochloride Injection, USP, but confirmed to contain Cisatracurium

Terminated Labeling / mix-up Meitheal Pharmaceuticals Inc NDC 71288-712-05 D-0286-2021
Class II · Moderate risk

Cephalexin for Oral Suspension

CGMP Deviations: Individual Unidentified impurities results of the product was found at higher side of the specification limit.

Terminated Impurity / degradation Ascend Laboratories LLC NDC 67877-545-68 D-0264-2021
Class II · Moderate risk

Cephalexin for Oral Suspension

CGMP Deviations: Individual Unidentified impurities results of the product was found at higher side of the specification limit.

Terminated Impurity / degradation Ascend Laboratories LLC NDC 67877-545-88 D-0263-2021
Class II · Moderate risk

Lidocaine/Tetracaine

Superpotent Drug. Lidocaine higher concentration than listed

Terminated Wrong potency / content Stanley Specialty Pharmacy Compounding and Wellness Center D-0252-2021
Class II · Moderate risk

Famotidine Tablets USP 40mg

Presence of foreign tablets/capsules: Famotidine 20mg and ibuprofen 400mg tablets were found in a lot of famotidine 40mg.

Terminated Particulate / foreign matter Aurobindo Pharma USA Inc. NDC 65862-860-99 D-0290-2021
Class I · High risk

Benzonatate capsules

Labeling: Label Mix-up: Bottle labeled as Benzonatate 100 mg capsules contained Benzphetamine 50 mg tablets and a bottle labeled as Benzphetamine 50 mg tablets contained Benzonatate 100 mg capsules.

Terminated Labeling / mix-up Calvin Scott & Company, Inc. NDC 67877-0573-05 D-1124-2022

Recalls by year